BR112022025901A2 - Composições e métodos para tratar transtorno obsessivo-compulsivo - Google Patents

Composições e métodos para tratar transtorno obsessivo-compulsivo

Info

Publication number
BR112022025901A2
BR112022025901A2 BR112022025901A BR112022025901A BR112022025901A2 BR 112022025901 A2 BR112022025901 A2 BR 112022025901A2 BR 112022025901 A BR112022025901 A BR 112022025901A BR 112022025901 A BR112022025901 A BR 112022025901A BR 112022025901 A2 BR112022025901 A2 BR 112022025901A2
Authority
BR
Brazil
Prior art keywords
compulsive disorder
compositions
methods
obsessive
treat obsessive
Prior art date
Application number
BR112022025901A
Other languages
English (en)
Portuguese (pt)
Inventor
Coric Vladimir
Berman Robert
Aguiar Loren
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of BR112022025901A2 publication Critical patent/BR112022025901A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022025901A 2020-06-24 2021-06-24 Composições e métodos para tratar transtorno obsessivo-compulsivo BR112022025901A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043681P 2020-06-24 2020-06-24
PCT/US2021/038789 WO2021262914A1 (en) 2020-06-24 2021-06-24 Compositions and methods for treating obsessive-compulsive disorder

Publications (1)

Publication Number Publication Date
BR112022025901A2 true BR112022025901A2 (pt) 2023-01-10

Family

ID=79281806

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025901A BR112022025901A2 (pt) 2020-06-24 2021-06-24 Composições e métodos para tratar transtorno obsessivo-compulsivo

Country Status (12)

Country Link
US (1) US20230181541A1 (https=)
EP (1) EP4171554A4 (https=)
JP (1) JP7805969B2 (https=)
KR (1) KR20230027189A (https=)
CN (1) CN115968312A (https=)
AU (1) AU2021297249A1 (https=)
BR (1) BR112022025901A2 (https=)
CA (1) CA3187323A1 (https=)
IL (1) IL299301A (https=)
MX (1) MX2022016174A (https=)
PH (1) PH12022553441A1 (https=)
WO (1) WO2021262914A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2400349A1 (hu) * 2024-07-05 2026-01-28 Egis Gyógyszergyár Zrt. Troriluzole-hidroklorid-sók

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564187T3 (es) * 2005-04-05 2016-03-18 Yale University Agentes de modulación de glutamato en el tratamiento de trastornos mentales
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
JP2018521007A (ja) * 2015-05-22 2018-08-02 ヴィスタゲン セラピューティクス、インコーポレイテッド Ｌ−４−クロロキヌレニンの治療的使用
TW202000205A (zh) * 2018-02-21 2020-01-01 美商Ａｉ治療公司 使用阿吡莫德與麩胺酸性劑的組合治療
MX2020012377A (es) * 2018-05-27 2021-04-12 Biohaven Therapeutics Ltd Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
MX2021000515A (es) * 2018-07-22 2021-06-08 Biohaven Therapeutics Ltd Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
US20210315865A1 (en) * 2018-08-16 2021-10-14 Biohaven Therapeutics Ltd. Use of riluzole oral disintigrating tablets for treating diseases

Also Published As

Publication number Publication date
AU2021297249A1 (en) 2023-02-23
WO2021262914A1 (en) 2021-12-30
IL299301A (en) 2023-02-01
EP4171554A1 (en) 2023-05-03
US20230181541A1 (en) 2023-06-15
PH12022553441A1 (en) 2024-03-04
MX2022016174A (es) 2023-01-24
CA3187323A1 (en) 2021-12-30
CN115968312A (zh) 2023-04-14
KR20230027189A (ko) 2023-02-27
JP2023531919A (ja) 2023-07-26
JP7805969B2 (ja) 2026-01-26
EP4171554A4 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
MX389242B (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares
MY209831A (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
BR112014010803A2 (pt) método de tratamento
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112015023725A2 (pt) composição de dosagem de filme autossuportante, composição de dosagem de filme, método de tratamento, e, processo de formação de composição de dosagem de filme
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
TN2019000019A1 (en) Treatment and prevention of sleep disorders
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
BR112022023928A2 (pt) Uso de canabidiol para o tratamento do transtorno do espectro autista
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
MX2023004113A (es) Metodo para el tratamiento de enfermedades relacionadas con ox40.
BR112019008241A2 (pt) tratamento do prurigo nodular
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
BR112022025901A2 (pt) Composições e métodos para tratar transtorno obsessivo-compulsivo
BR112018069174A2 (pt) tratamento de prurido urêmico
EA202193276A1 (ru) Способы лечения холангиокарциномы
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX2024004514A (es) Terapia de combinacion con el inhibidor de o-glcnacasa (oga).
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2025000682A (es) Composicion farmaceutica de anticuerpo anti-cd20 y uso de la misma